“…Clopidogrel is a thienopyridine and the choice of drug for the prevention of thrombosis associated with cardiovascular stenting; however, 20-40 % of patients respond poorly to this, and therefore, alternatives such as prasugrel, vicagrel, ticagrelor, cangrelor and elmogrel are being used instead (Zhang and Hollenberg, 2014). Recent developments in platelet aggregation inhibitors have been the identification of a preclinical candidate (SAR216471), an indole-3-carboxamide that irreversibly binds to the P2Y12 receptor involved in adenosine diphosphate (ADP) stimulated platelet activation of the glycoprotein IIb/IIIa (Boldron et al, 2014), 2-phenylpyrimidine-4-carboxamides as orally bioavailable and selective P2Y12 antagonists (Caroff et al, 2014), a pyrimidine-7-carboxamide, an orally bioavailable PI3Kb inhibitor with potent in vivo anti-thrombotic effects (Giordanetto et al, 2014) and a tick peptide YY-39, which was found to inhibit platelet aggregation induced by ADP, thrombin and thromboxane A2(TXA2) (Tang et al, 2014).…”